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Abstract
Background
Dengue laboratory diagnosis is essentially based on detection of the virus, its components
or antibodies directed against the virus in blood samples. Blood, however, may be difficult
to draw in some patients, especially in children, and sampling during outbreak investiga-
tions or epidemiological studies may face logistical challenges or limited compliance to inva-
sive procedures from subjects. The aim of this study was to assess the possibility of using
saliva and urine samples instead of blood for dengue diagnosis.
Methodology/Principal Findings
Serial plasma, urine and saliva samples were collected at several time-points between the
day of admission to hospital until three months after the onset of fever in children with con-
firmed dengue disease. Quantitative RT-PCR, NS1 antigen capture and ELISA serology for
anti-DENV antibody (IgG, IgM and IgA) detection were performed in parallel on the three
body fluids. RT-PCR and NS1 tests demonstrated an overall sensitivity of 85.4%/63.4%,
41.6%/14.5% and 39%/28.3%, in plasma, urine and saliva specimens, respectively. When
urine and saliva samples were collected at the same time-points and tested concurrently,
the diagnostic sensitivity of RNA and NS1 detection assays was 69.1% and 34.4%, respec-
tively. IgG/IgA detection assays had an overall sensitivity of 54.4%/37.4%, 38.5%/26.8%
and 52.9%/28.6% in plasma, urine and saliva specimens, respectively. IgM were detected
in 38.1% and 36% of the plasma and saliva samples but never in urine.
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Conclusions
Although the performances of the different diagnostic methods were not as good in saliva
and urine as in plasma specimens, the results obtained by qRT-PCR and by anti-DENV
antibody ELISA could well justify the use of these two body fluids to detect dengue infection
in situations when the collection of blood specimens is not possible.
Author Summary
Dengue is the most important arthropod-borne disease affecting humans and represents a
huge public health burden in affected countries. Symptoms are often non-specific hence
the need for an early, sensitive and specific diagnosis of dengue for appropriate manage-
ment as well as for early epidemic detection. Currently, almost all laboratory diagnostic
methods require a blood specimen that may be sometimes be difficult or inconvenient to
obtain. In this study, we assessed the possibility to use saliva and urine samples as alterna-
tives to blood specimens in dengue diagnosis. We demonstrated that the performances of
the different diagnostic methods (RT-PCR, NS1 antigen detection and anti-DENV IgM/
IgG/IgA ELISAs) were in general not as good in saliva and urine as in plasma, but that the
use of these body fluids obtained by non-invasive methods could be of value in certain cir-
cumstances such as outbreak investigations or in young children (once they are old
enough to comply to instructions), in addition to the situations when blood cannot be eas-
ily collected (e.g., lack of phlebotomist, refusal of the procedure, etc.).
Introduction
Dengue virus (DENV; family Flaviviridae, genus Flavivirus), is a mosquito-borne, enveloped,
single stranded positive-sense RNA virus. Until recently, four serologically related but antigeni-
cally and genetically distinct dengue viruses (DENV-1, -2, -3,and -4) causing disease in human
were known, but a fifth serotype was recently discovered in Malaysia [1,2].
Over the last decades, DENV has become the most important arthropod-borne virus affect-
ing humans. Several factors such as rapid urbanization, failure to control mosquitoes and rapid
progress in air transportation have contributed to the emergence of endemic dengue in 128
countries in the world [3,4]. In 2009, the World Health Organization (WHO) estimated that
2.5 billion people were living in areas at high risk for infection, among which 50 million were
infected annually [1]. However due to weak disease surveillance, low level of reporting of cases
and difficulties in diagnosis, the true incidence and burden of dengue are very likely under esti-
mated. Using new modeling approaches, Bhatt et al. estimated that approximately 3.97 billion
people were living in areas where DENV is circulating and that almost 400 million cases of
dengue occurred every year worldwide [4].
While most infections are asymptomatic or result in a mild febrile illness, the virus is capa-
ble of producing life-threatening dengue hemorrhagic fever, dengue shock syndrome, and
non-specific complication of systemic diseases (e.g. encephalitis, hepatitis) [1]. The course of
dengue illness can be divided in three main phases: the febrile phase, the critical phase and the
recovery phase. Severe clinical disease manifestations such as fluid leakage, bleeding and shock
occurs during the critical phase which begins around day 4–7 after the onset of fever, when the
temperature drops under 38°C, and lasts usually between 48 to 72 hours. During the critical
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phase, the condition of patients experiencing a severe form of the disease worsens as a result of
plasma leakage whereas the condition of patients with a non-severe disease improves.
Direct diagnosis of DENV infection is based on virus isolation, detection of the viral genome
by reverse transcription polymerase chain reaction (RT-PCR) or detection of NS1 antigen.
Indirect diagnosis using serological methods to detect anti-DENV IgM and IgG is commonly
employed, while IgA tests remain less commonly used. The selection of diagnostic methods
depends greatly on the time-point of the sample collection during the course of the disease.
RT-PCR and virus isolation require a blood sample collected during the early febrile phase of
the disease (0–5 days after the onset of fever) [1]. A sample obtained during the early phase is
also preferred for NS1 detection, but in patients experiencing a primary infection the NS1 anti-
gen remains detectable for nine days or more after the onset of fever [5,6]. Serological methods
can be used later during the course of the disease. IgM and IgA, however, can persist in blood
during several weeks or even months after the infection while IgG may persist for decades. Dif-
ferentiating between an acute and a recent DENV infection by these methods may therefore be
challenging. Currently almost all laboratory diagnostic methods require a blood sample that
may be difficult to obtain in children, the population which is most commonly affected by den-
gue in endemic regions, especially in field conditions or outbreak settings. Saliva and urine
samples could be used as surrogates for blood as the collection of these body fluids is non-inva-
sive and better accepted by patients, does not require medically-trained staff and the samples
are easier to process as they require only limited laboratory facilities.
Diagnosis using urine and saliva samples has already been explored for several other viral
infections such as HIV, Hepatitis A, B and C and rubella [7–13]. Urine specimens seem suitable
for the diagnosis of infection by West-Nile virus (WNV) and Zika virus (ZIKV)–two other fla-
viviruses—as viral genome of both viruses can be detected longer in urine than in serum
[14,15] and infectious WNV and ZIKV can be recovered from urine [16–18]. Previous studies
conducted on a limited number of samples have demonstrated that urine and saliva could be
used as an alternative to blood for serological or virological diagnosis of dengue [19–29].
The purpose of this study was to describe the excretion profiles of the anti-DENV antibodies
(IgG, IgM and IgA), the NS1 antigen, the viral genome and of the infectious virus in plasma,
saliva and urine specimens obtained from a large number of Cambodian children with a con-
firmed dengue infection. In this study, we aimed to evaluate the possibility of using saliva and
urine as alternatives to serum or plasma samples. We also aimed to assess if urine and/or saliva
specimens could contribute to predict progression towards a severe form of the disease, as sug-
gested by Chuansumrit et al. [21], or if the use of such specimens increases the time window
for DENV infection confirmation as suggested by several previous studies [20,22,24].
Materials and Methods
Clinical samples
Plasma, saliva and urine samples used in this study were collected in Cambodia in 2013, during
the DENFREE (DENgue research Framework for Resisting Epidemics in Europe) study [30].
Samples were prospectively obtained from children hospitalized with clinically-suspected den-
gue in one of the three hospitals of the Kampong Cham province participating to the DEN-
FREE study. Dengue infection was confirmed in patients through a combination of: viral RNA
detection by quantitative RT-PCR (qRT-PCR); isolation of the virus in cell culture; detection of
the NS1 protein in the blood; by evidencing a IgM seroconversion in paired plasma and/or a
fourfold increase of the antibody titer measured by hemagglutination inhibition assay (HIA) in
paired plasma collected at least seven days apart. Disease severity was assessed for each patient
according to the 1997 WHO criteria and to the 2009 WHO guidelines [1, 31] using clinical,
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biological and paraclinical examination data recorded at admission and throughout the entire
hospitalization period. Patients were classified into 2 groups: non-severe dengue (dengue fever
(DF) according to the 1997 guidelines and DF without warning signs according to the 2009WHO
guidelines) and severe dengue (dengue hemorrhagic fever (DHF) and DSS (dengue shock syn-
drome) according to the 1997 guidelines and dengue with warning signs as well as severe dengue
according to the 2009WHO recommendations). Urine and saliva were collected daily during hos-
pitalization and then one week, two weeks, three weeks, one month and three months after the
discharge from hospital. Plasma specimens were collected at three time-points during hospitaliza-
tion: on admission, during hospitalization and at the time of hospital discharge. If the patient or
guardians gave consent, blood was also collected 30 and 90 days after leaving the hospital.
Urine specimens were collected in 50 ml sterile tubes. Due to the large volume of saliva
required for the analyses, the saliva specimens were obtained by direct spitting into 1.8 ml ster-
ile tubes. If possible, children were asked to spit into two separate tubes, an empty one and a
pre-filled one with 100µl of viral transport medium (VTM), until minimal volumes of 100 µl
and 200 µl were reached in the empty and the pre-filled tubes, respectively. All clinical samples
were stored at -80°C prior to testing. In addition to prevent degradation of the RNA and of the
virus infectivity, the freezing process was also beneficial to reduce the viscosity of the saliva.
Only patients with well-documented medical records allowing a clear assessment of the dis-
ease severity were included in this study.
The clinical specimens obtained from 20 patients hospitalized for a non-dengue febrile ill-
ness were also used to assess the specificity of the different diagnostic methods in urine and
saliva samples. These controls showed no biological evidences of on-going DENV infection
(DENV qRT-PCR negative, NS1 test negative and no anti-DENV antibodies in paired plasma
[admission and discharge]).
Viral genome detection
The viral RNA was extracted from 140 µl of plasma, 280 µl of saliva mixed with VTM and
280 µl of concentrated urine, using the QIAmp Viral RNAMini kit (Qiagen, Germany). Urine
samples were concentrated using the 100K Microsep ultrafiltration device (Pall, USA) to con-
vert an initial volume of 5 ml urine to a final volume of 280 µl of concentrated urine. After
extraction, the DENV nucleic acids present in plasma were detected by a serotype-specific
quantitative multiplexed real-time RT-PCR (qRT-PCR) as previously described by Hue et al.
[32]. For urine and saliva, the multiplex qRT-PCR was replaced by a monoplex qRT-PCR as the
serotype was already identified in the corresponding plasma. Results were expressed in equiva-
lents to complementary DNA (cDNA) copies per ml. The limit of detection in plasma was 350
copies/ml for DENV-1, 75 copies/ml for DENV-2, 350 copies/ml for DENV-3 and 715 copies/ml
for DENV-4. The limit of detection was 200 copies/ml, 50 copies/ml, 200 copies/ml and 350 cop-
ies/ml for DENV-1, -2, -3 and -4, respectively, with the qRT-PCR in urine and plasma specimens
spiked with quantified synthetic plasmids.
As DENV viremia lasts only a few days after the onset of fever (DAOF), the samples selected
for the detection of the viral genome were mainly those collected during hospitalization. Addi-
tional urine and saliva specimens collected one to three weeks after discharge from the hospital
were also added as some data previously published suggested that the DENV genome could be
detected in urine until day 16 after the onset of fever [22].
Virus isolation in C6/36 cells
C6/36 cells were used in attempt to isolate DENV from urine and saliva samples. Before inocu-
lation, urine samples were dialyzed and concentrated in PBS using the 100K Microsep
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ultrafiltration system (Pall, USA) and then filtered through 0.2-μmmembrane (Nalgene
Thermo Scientific, USA). Saliva diluted in VTM as well as urine samples were diluted 1/2 with
L15 Leibovitz Medium (Sigma Aldrich, Germany) containing 2% of fetal calf serum (Gibco
Life Technology, USA). Final volumes of 300 µl of diluted specimens, or controls, were inocu-
lated into 12-well plates containing 100% confluent C6/36 cells and incubated for 1 hour at
28°C. After incubation, 1.7 ml of medium was added to each well and the plates were incubated
at 28°C. After 7 days, cells were harvested and DENV was detected by an immunofluorescence
assay using serotype-specific monoclonal antibodies as described previously [33]. For samples
that tested negative, two additional passages on C6/36 were performed before concluding that
DENV did not replicate.
Our positive controls consisted of urine and saliva specimens obtained from healthy indi-
viduals as well as VTM spiked with infectious virus at a final concentration of 3 to 7 log10
cDNA copies/ml. Spiked urine controls were dialyzed and concentrated as for the patient’s
urine samples.
NS1 detection by ELISA
A capture ELISA was used to detect NS1 in plasma, non-concentrated urine and undiluted
saliva. In plasma and urine, the NS1 protein was detected by the two-step ELISA method
described by Alcon et al. [6] but after replacing polyclonal antibodies by monoclonal antibod-
ies. For the saliva specimens, a one-step capture ELISA was used. All the protocols are detailed
in S1 Table. Briefly, in the one-step ELISA developed for NS1 detection in saliva, the sample
and the conjugated antibody were incubated together for 2 hours. In the two-step ELISAs
(used for plasma and urine specimens), samples were first incubated for one hour and then
after a washing step, the conjugated antibody was added and incubated for one hour.
For the patients infected with DENV-1, the NS1 protein was quantified by ELISA using
serial two-fold serial dilutions of a solution containing a known concentration of affinity-puri-
fied DENV-1 recombinant NS1 protein expressed in HEK293T cells (kindly provided by Dr.
Marie Flamand, Institut Pasteur, Paris, France). The standard curve was linear between 0.5 ng/
ml and 16 ng/ml for all three NS1 assays. A result was considered positive if the OD was greater
than twice the mean OD value measured in 20 negative controls (20 healthy children enrolled
during the community study of DENFREE project).
Two positive controls, a weak one and a strong one, and one negative control were used to
validate the results of each plate. Inter- and intra-precision of the different ELISAs are shown
in S4 and S5 Tables. The samples used for the NS1 protein detection were mainly those col-
lected between DAOF 1 and 10 in hospitalized patients. In addition, 29 urine and 7 saliva spec-
imens collected between DAOF 10 and 16 were tested.
IgM and IgA detection by MAC-ELISA and AAC-ELISA and IgG
detection by indirect ELISA
In-house capture ELISAs were used to detect anti-DENV IgM (MAC-ELISA) and IgA
(AAC-ELISA) in plasma, non-concentrated urine and undiluted saliva specimens. For plasma,
MAC-ELISA and AAC-ELISA were performed as described previously [33,34]. For urine and
saliva samples, minor modifications to MAC-ELISA and AAC-ELISA protocols were adopted.
A 100 µl/well format was used for plasma and urine samples, but as only a limited volume of
saliva was available, a 50 µl/well format was used for this body fluid. The protocols used are
detailed in S2 and S3 Tables. One negative control, one weakly positive control and one
strongly positive control were tested in each plate in order to validate each plate of tests. Inter-
and intra-precision of the different assays are shown in S4 and S5 Tables.
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Results were expressed as ΔODs (OD of the sample incubated in the presence of antigen—
OD of the sample incubated in the absence of antigen). A result was considered as positive
when the ΔOD was higher than 0.05 for the saliva-based AAC-ELISA and higher than 0.1 for
all the other ELISAs. The cut-offs were determined by testing the samples from 20 healthy chil-
dren who showed no biological evidences of a previous DENV infection (DENV qRT-PCR
negative, NS1 ELISA negative and HI titer = 0). Cut-off values are shown in S1 Fig.
In-house indirect ELISAs were used to detect anti-DENV IgG in plasma, non-concentrated
urine and undiluted saliva specimens [35]. A 100 µl/well format was used for the plasma and
urine-based ELISAs, while a 50 µl/well format was used for the saliva-based ELISA, due to the
limited volume of samples available. The protocols used here are described in S6 Table.
Results were expressed as ΔODs. Results were considered as negative when the ΔOD was
below 0.2 for the ELISA in plasma (cut-off determined by comparing ELISA results to those
obtained by HIA with the same samples) and below 0.1 for the ELISAs in urine and saliva. Cut-
off values were determined by testing the samples obtained from 20 healthy children and are
described in S1 Fig.
For the evaluation of the antibody detection assays, the samples tested were collected during
the hospitalization as well as during the follow-up period after the patient was discharged from
the hospital. The panel contained samples collected as early as the day of the onset of fever as
well as specimens obtained up to 103 days after the beginning of the disease.
Statistical analysis
Statistical analysis was performed using STATA version 11.0 (StataCorp, USA). A significance
was assigned at P<0.05 for all parameters and were two-sided. The statistical differences
between various categorical groups were detected using Chi-squared test. Correlation coeffi-
cients between two continuous variables were calculated using Spearman’s rank correlation
test. Uncertainty was expressed by 95% confidence intervals (CI95).
In order to identify explanatory variables associated with the detection of the viral genome,
the NS1 antigen or the anti-DENV antibodies in the three different fluids, multivariate analysis
using a boosted regression tree (BRT) approach was used. BRT is a method combining regres-
sion trees with weak individual predictive performances into a single model with higher perfor-
mance. We used BRT because it is capable of dealing with complex responses, including non-
linear relationships and interactions between explanatory variables [36], and we were expecting
such complex relationships between our explanatory and response variables. As part of the
final model, the BRT assesses the relative importance (RI) of each explanatory variable based
on the number of times a variable is used in all trees and its contribution to the final model
improvement. A higher RI of a predictor indicates a stronger influence on the response in ques-
tion (i.e. the detection of each diagnostic marker, in this study). The effect of each explanatory
variable on the response can be visualized by the use of partial dependence plots. For each
model with a binary response variable, a Receiver-Operating Characteristic (ROC) curve was
constructed and the area under the ROC curve (AUC) was calculated. The AUC ranges
between 0.5 for random prediction to 1, the higher the AUC the better the model performance.
For models with a continuous response variable, the performance of the model was estimated
by a correlation coefficient between observed and predicted datasets. This correlation coeffi-
cient ranges between 0 (no correlation) and 1 (perfect correlation), with values superior to 0.5
suggesting a high correlation. The analysis was carried out using the “dismo” package (version
1.0–5) [37] and the “gbm” package (version 2.1) [38] under the R statistical environment (R
Foundation, Vienna, Austria). A learning rate of 0.001, a bag fraction of 0.5 and a tree complex-
ity of 3 were used. The explanatory variables used are summarized in Table 1. The dengue
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serotype was not included in the analyses as most of the patients included in this study were
infected with a DENV-1 strain during the 2013 epidemic in Cambodia.
Ethical aspects
The children’s legal representatives signed a written consent before the enrolment of the
patient. The DENFREE project was approved by the Cambodian National Ethics Committee
for Health Research (authorization no. 063NECHR).
Results
Dengue infection was confirmed in 401 of 574 children hospitalized with clinically-suspected
dengue included in the DENFREE study between June and September 2013. In total, 913
plasma, 1555 urine and 1564 saliva samples obtained from 267 patients with confirmed dengue
infection and complete records were analyzed. The patients were 3 to 16 years old (median age:
9 years) and 57.3% (153/267) were male. Because of sample volume limitations, all patients
may not have been included in each laboratory test evaluation. For each patient, between one
to eight urine (median = 4), one to six saliva (median = 3) and one to six plasma (median = 3)
samples were collected. Among these samples, a total of 763 matched plasma, urine and saliva
samples were obtained from the individual patients at the same time-point during the course
of the disease. The number of patients as well as the number and the characteristics of the sam-
ples used to evaluate each assay are summarized in Table 2.
Viral genome detection
Overall, 85.4% (323/378, CI95 = [81.5–88.8]) of the plasma specimens obtained from 144
patients with a confirmed acute DENV infection and sampled from the day of onset of fever
until the 10th day after fever onset, tested positive. Out of the 442 urine and the 562 saliva sam-
ples obtained between the day of fever onset until the 28th day after the onset of fever (DAOF
28) from 118 and 132 patients, respectively, 41.6% (n = 184, CI95 = [37.0–46.4]) and 39%
(n = 219, CI95 = [34.9–43.1]) tested positive by qRT-PCR. The qRT-PCR results are presented
based on days of sampling after the onset of fever (Fig 1, S7 Table, S9 Table). The proportion of
urine samples positive by qRT-PCR increased with time, starting from a minimum of 13.6%
during the first 2 days after fever onset to a maximum of 66.6% at DAOF 9–10. At the latest
Table 1. Explanatory variables used in the different BRTmodels.
Name Description Variable type
daof Number of day between the onset of fever and the
time of sampling
Continuous
status Immune status of the patient determined by HIA Categorical (Primary infection /
Secondary infection / Unknown)
classif Disease severity classification according to 1997
WHO guideline
Categorical (Non severe / Severe)a
logvir Viral load measured by qRT-PCR (log10 cDNA
copies/ml)
Continuous
logNS1 NS1 concentration in plasma (log10 ng/ml) Continuous
antibodies Quantity of anti-DENV antibodies in plasma
estimated by optical density in ELISA
Continuous
a Non severe disease refers to dengue fever (DF) and severe disease refers to dengue hemorrhagic fever
(DHF) and dengue with shock syndrome (DSS)
doi:10.1371/journal.pntd.0004100.t001
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Table 2. Characteristics of the samples used in each part of the study.
Plasma Urine Saliva
Complete study
Total number of samples 913 1555 1564
Total number of patients 267 267 267
Viral genome detection
Total number of samples 378 442 562
Total number of patients 144 118 132
Immune status
Primary infection 107 139 172
Secondary infection 185 206 269
Undetermineda 86 97 121
Serotype
DENV-1 273 369 401
DENV-2 40 44 61
DENV-3 0 0 0
DENV-4 65 29 100
qRT-PCR negative 0 0 0
Disease classificationb
Non severe 210 228 317
Severe 168 214 245
Sample collection
At admission and during hospitalization 378 423 551
After hospital discharge 0 19 11
NS1 detection
Total number of samples 533 859 688
Total number of patients 217 193 197
Immune status
Primary infection 157 240 201
Secondary infection 267 446 342
Undetermineda 109 173 145
Serotype
DENV-1 365 592 481
DENV-2 44 54 58
DENV-3 9 19 17
DENV-4 86 147 111
qRT-PCR negative 29 47 21
Disease classificationb
Non severe 341 542 477
Severe 192 317 211
Sample collection
At admission and during hospitalization 533 839 687
After hospital discharge 0 20 1
Antibodies detection
Total number of samples 876 1,493 1,489
Total number of patients 255 219 227
Immune status
Primary infection 253 469 425
Secondary infection 450 735 784
(Continued)
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time-points, the proportion of urine samples positive by qRT-PCR was approximately the
same as the proportion of RNA-positive plasma specimens (71.4% and 62.5% at DAOF 9–10,
respectively). DENV RNA remained detectable in one urine sample at DAOF 16. The detection
rate of viral RNA by qRT-PCR in saliva samples followed the decreasing curve of the RNA
detection rate observed in the plasma specimens. The highest proportion of saliva samples that
tested positive for DENV RNA was observed between the first day and the 4th day of fever
(60.5% at DAOF 0–2, 63.9% at DAOF 3 and 58.5% at DAOF 4) whereas plasma samples col-
lected at the same time-points were RNA-positive in 96% to 100% of the cases. The RNA detec-
tion rate in saliva decreased thereafter (44.2%, 30.9%, 23.9%, 9.9%, 16% and 8.3% at DAOF 5,
6, 7, 8, 9 and 10, respectively), and all samples tested negative after DAOF 10. By comparison
with the percentage of plasma samples positive by qRT-PCR, the sensitivity of qRT-PCR in
saliva was on average 46.2% lower, with a minimal difference of 36.1% at DAOF 3 and a maxi-
mal difference of 55.4% at DAOF 9.
In total, 57.6% (68/118) of the patients had at least one of their urine samples that tested
positive by qRT-PCR and 68.9% of them (92/132) had at least one saliva sample that tested
positive.
When only considering the 243 matched plasma, urine and saliva samples (i.e clinical speci-
mens collected from the same patients at the same time-points) obtained between DAOF 1 and
DAOF 12, the proportion of specimens that tested positive by qRT-PCR was 90.5% (220/243,
CI95 = [86.1–93.9]), 39.9% (97/243, CI95 = [33.7–46.4]) and 49.8% (121/243, CI95 = [43.3–
56.3]) for plasma, urine and saliva, respectively (Table 3). Three urine samples that tested posi-
tive had a corresponding matched plasma sample that tested negative. These 3 urine samples
were all collected at the time of hospital discharge: one at DAOF 6 and the two others at DAOF
10. Testing by qRT-PCR the urine and the plasma specimens led to an increase of the diagnos-
tic sensitivity: 90.5% of sensitivity if the plasma was tested alone, 91.8% when both urine and
plasma specimens were tested in parallel. The diagnostic sensitivity increased from 85% for
plasma samples alone to 86.7% for the plasma and urine combination with samples collected at
DAOF 6–7 and from 70.7% to 75.6% during the second week after fever onset. All subjects
whose saliva samples tested positive also had detectable RNA levels in their corresponding
plasma samples. If both the urine and the saliva samples collected at the same time-points were
screened for DENV-RNA the diagnostic sensitivity increased to 69.1% (168/243, CI95 = [62.9–
74.9]). If saliva and urine specimens were tested in parallel instead of testing the plasma, the
Table 2. (Continued)
Plasma Urine Saliva
Undetermineda 173 289 280
Disease classificationb
Non severe 586 1,005 1,010
Severe 290 488 479
Sample collection
At admission and during hospitalization 690 1,020 997
After hospital discharge 186 473 492
aImmune status is undetermined when the interval between admission and hospital discharge is < 7 days and the HI titer at the time of hospital discharge
is 2560
b non-severe dengue corresponds to dengue fever (DF) according to the 1997 guidelines and to DF without warning signs according to the 2009 WHO
guidelines. Severe dengue corresponds to dengue hemorrhagic fever (DHF) and DSS (dengue shock syndrome) according to the 1997 guidelines and
dengue with warning signs and severe dengue according to the 2009 WHO recommendations.
doi:10.1371/journal.pntd.0004100.t002
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overall diagnostic sensitivity decreased by 21.4% (by 16.7% if the samples were collected at
DAOF 0–1 or at DAOF 6–7, by 22.4% at DAOF 3–4, by 23% at DAOF 4–5, and by 24.4% for
samples obtained during the 2nd week after the onset of fever).
All clinical specimens obtained from 20 patients hospitalized for a non-dengue febrile illness
tested negative.
On average, 8.2 log10 cDNA copies/ml (min = 2.4 log10 and max = 9.9 log10 cDNA copies/
ml) were detected in plasma samples collected between DAOF 0 and 10, 3.5 log 10 cDNA cop-
ies/ml (min = 1 log 10 and max = 5.2 log10 cDNA copies/ml) were measured in urine speci-
mens obtained between DAOF 1 and 16, and 4.6 log10 cDNA copies/ml (min = 1.1 log10 and
max = 6.1 lon10 cDNA copies/ml) were detected in saliva specimens collected between DAOF
1 and 10. The results from 261, 167 and 164 sequential positive plasma, urine and saliva sam-
ples collected between DAOF 1 and 10 and obtained from 103, 57 and 54 patients, respectively,
were used to estimate the mean viral load according to the DAOF. The results are presented in
Fig 2. Briefly, before the 4th day after the onset of fever, the mean viral load in plasma was at its
maximum, at approximately 8.5 log10 cDNA copies/ml. Thereafter, the mean viral load in
those samples that tested positive progressively decreased over time. The mean viral load in
urine increased from 2.1 to 3.8 log10 cDNA/copies from the 2nd day until the 5th day after
onset of fever. Then it decreased very slowly until DAOF 9 before significantly dropping at
DAOF 10. Until DAOF 6, the mean viral load in saliva specimens that tested positive by
qRT-PCR was approximately 3.5 log10 lower than in plasma. From DAOF 7, the mean viral
load in saliva continued to only very slightly decrease and at DAOF 9 reached the same level
Fig 1. Detection of DENV RNA by qRT-PCR in plasma, urine and saliva specimens. Percentage of plasma, urine and saliva specimens that tested
positive for DENV RNA, by day of sampling after onset of fever. (n = 144 patients for plasma, 118 for urine and 144 for saliva).
doi:10.1371/journal.pntd.0004100.g001
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than in plasma. The viral load measured in saliva correlated with the viral load measured in
plasma (Spearman coefficient = 0.51, p-value<0.001) whereas there was no correlation
between viral loads in plasma and in urine (p-value = 0.28).
Virus isolation in C6/36 cells
In total, 15 urine and 15 saliva samples that tested positive by qRT-PCR with a high viral load,
i.e. between 3.5 and 5 log10 cDNA copies/ml, were inoculated onto C6/36 mosquito cells. Even
after 3 passages, all cell cultures remained negative by immunofluorescence assay. DENV was
isolated only from VTM, urine and saliva controls spiked with virus at a concentration equal to
or greater than 4 log10 cDNA copies/ml but not when the initial virus concentration was
lower. No cell death was observed in the wells inoculated with the three different negative con-
trols i.e., cell culture medium, dialyzed urine samples and saliva samples obtained from healthy
donors.
NS1 detection by capture ELISA
A total of 856 urine and 688 saliva samples obtained from 193 and 197 patients with confirmed
dengue were tested. In total, 14.5% (n = 124, CI95 = [12.2–17.0]) of the urine samples and
28.3% (n = 195, CI95 = [25–31.9]) of the saliva samples tested positive by NS1 ELISA. By com-
parison, 63.4% (338/533, CI95 = [59.2–67.5]) of all plasma samples obtained from hospitalized
patients and included in this study tested positive for NS1 (S7 Table, S9 Table).
The positivity rates of NS1 antigen detection in plasma, urine and saliva samples by day of
sampling after the onset of fever are presented in Fig 3 and S7 Table. The NS1 protein was
detected in 15.4% of the saliva and in 3.2% of the urine specimens at the beginning of the dis-
ease. This percentage increased to reach a maximum of 42.6% in saliva samples and 24.3% in
urine specimens at DAOF 4. The proportion of NS1-positive samples then decreased slowly
Fig 2. Mean viral loadmeasured by qRT-PCR in plasma, urine and saliva.
doi:10.1371/journal.pntd.0004100.g002
Use of Urine and Saliva for Dengue Diagnosis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004100 September 25, 2015 12 / 30
until DAOF 10 and no sample tested positive after that time-point. In plasma, the proportion
of samples that tested positive for NS1 was the highest (88.2%) at DAOF 3 and then progres-
sively decreased over time. At DAOF 9, the last time-point at which the plasma specimens
were tested, 22.2% of the samples tested positive by NS1 ELISA.
In total, 46.2% (91/197) and 37.8% (73/193) of the patients tested positive in NS1 capture
ELISA in at least one of their saliva and urine samples. Among the 91 patients that had at least
one NS1-positive saliva sample, the first specimen collected at admission tested positive in 67%
(n = 61) of the cases. Among the 73 patients that had at least one of their urine samples that
tested positive, only 41.1% (n = 30) had a positive urine sample at the time of hospital admis-
sion. Using the results obtained by testing the sequential biological samples collected through-
out the hospitalization, the median first day of the NS1 detection in urine was determined for
30 patients at DAOF 5 (mean = 5.1), with a minimum at DAOF 3 and a maximum at DAOF 9.
Based on a subset of 17 patients, we were able to establish that the median duration of NS1
antigen detection in the urine of a DENV-infected patient was 1 day (mean = 1.5), with a maxi-
mum of 3 days.
The NS1 antigen was detected in 70.9% (202/285), 27.4% (46/168) and 47.7% (73/153) of
the plasma, urine and saliva specimens that also tested positive by qRT-PCR. The NS1 ELISA
was also positive in 20.9% (9/43), 10.7% (21/196) and 20.7% (42/203) of the plasma, urine and
saliva samples that tested negative by qRT-PCR.
Fig 3. Positivity rates of NS1 protein detection in plasma, urine and saliva. Percentage of samples that tested positive for NS1 protein by capture ELISA
in urine, saliva and plasma, by day of sampling after onset of fever (n = 193, 197 and 217 patients with a confirmed dengue infection included for NS1
detection in urine, saliva and plasma, respectively).
doi:10.1371/journal.pntd.0004100.g003
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NS1 ELISA was used to test a total of 314 plasma, urine and saliva samples obtained from
the same patients at the same time-points, between DAOF 1 and DAOF 12. The results were
positive in 69.4% (218/314, CI95 = [64.0–74.5]), 15.9% (50/314, CI95 = [12.1–20.4]) and 30.6%
(96/314, CI95 = [25.5–36.0]) of the plasma, urine and saliva samples, respectively (Table 3). An
overall diagnostic sensitivity of 34.4% (108/314, CI95 = [29.2–39.9]) was obtained by combin-
ing the NS1 results of urine and saliva. If saliva and urine samples were tested together instead
of plasma, diagnostic sensitivity decreased to 16.7%, 34.9%, 49.5%, 32.2% and 10.9%, at day
0–1, 2–3, 4–5, 6–7 and during the second week after the onset of fever, respectively, while sensi-
tivity in plasma was 83.3%, 91.6%, 79%, 55.9% and 29.1% at the same time-points. Each time a
saliva or a urine sample tested positive, the NS1 antigen was also detected in the corresponding
plasma specimen. All clinical specimens obtained from 20 patients hospitalized for a non-den-
gue febrile illness tested negative.
Between DAOF 1 and 10, the average concentration of NS1 protein detected in the clinical
specimens was 889 ng/ml (min = 0.8 ng/ml and max = 8 µg/ml) in plasma, 7.2 ng/ml
(min = 0.5 ng/ml and max = 60 ng/ml) in urine and 3.8 ng/ml (min = 0.5 ng/ml and
max = 41.5 ng/ml) in saliva. The mean NS1 concentration in the plasma specimens increased
from 800 ng/ml at DAOF 1–2 to reach a maximal mean concentration of 1.2 µg/ml at DAOF
5–6. It then decreased to reach a concentration of 400 ng/ml at DAOF 8–10 (S2 Fig). The mean
NS1 concentration in urine was stable between DAOF3 and 5 (7 ng/ml) and increased at
DAOF 6 (14 ng/ml) and DAOF 7 (26 ng/ml) (S2 Fig). No significant variation in NS1 concen-
tration was observed over time in saliva samples (S2 Fig).
Detection of anti-DENV antibodies
A total of 100 urine specimens were initially tested by MAC-ELISA and since all of them were
negative we decided not to include additional samples to the evaluation panel. A total of 1493
and 1483 urine samples were used to evaluate the performances of the IgG and IgA ELISAs in
this biological fluid. Out of the 1489 saliva samples available for serological evaluation, 1123,
1395 and 1101 were used for the IgG, IgM and IgA assays, respectively. A total of 766, 678 and
778 plasma samples were tested by indirect IgG ELISA, MAC-ELISA and AAC-ELISA,
respectively.
Anti-DENV IgM were detected in 36% (244/678, CI95 = [32.4–39.7]) and 38.1% (531/1395,
CI95 = [35.5–40.7]) of all the plasma and saliva samples, respectively, while none of the urine
specimens (0/100) tested positive by MAC-ELISA. Overall 37.4% (291/778, CI95 = [34.0–
40.9]) of the plasma, 26.8% (397/1483, CI95 = [24.5–29.1]) of the urine samples and 28.6%
(315/1101, CI95 = [26.0–31.4]) of the saliva samples tested positive by AAC-ELISA. In total,
54.4% (417/766, CI95 = [50.8–58.0]) of the plasma samples, 38.5% (575/1493, CI95 = [36.0–
41.0]) of the urine samples and 52.9% (594/1123, CI95 = [49.9–55.8]) of the saliva specimens
tested positive by indirect IgG ELISA.
Fig 4 and S7 Table show the percentage of positive results obtained for anti-DENV IgM,
IgA and IgG detection in urine, saliva and plasma samples according to DAOF. The positivity
rates obtained for IgM, IgA and IgG antibodies detection in the saliva samples were slightly
lower than the ones observed for these antibodies in plasma specimens, but both kinetics were
in general very similar. MAC-ELISAs sensitivity increased until DAOF 7, to reach 86% and
73% in plasma and saliva, respectively. The sensitivity remained stable during the second week
of the disease and then decreased gradually over the following weeks. Six weeks after the onset
of the fever, 16% and 6% of the plasma and saliva samples tested positive. At three months, less
than 2% of the plasma and saliva samples still contained detectable levels of anti-DENV IgM.
Use of Urine and Saliva for Dengue Diagnosis
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The profiles of the sensitivity kinetic curves for anti-DENV IgA were similar in plasma,
urine and saliva specimens. The sensitivity increased until the second week after the onset of
fever to reach a maximum of 90% in the plasma and 65% in both the urine and the saliva
Fig 4. Detection of anti-DENV antibodies in plasma, urine and saliva. Percentage of samples that tested positive by MAC-ELISA (A), AAC-ELISA (B) and
IgG indirect ELISA (C) in urine, saliva and plasma samples according to time after onset of fever (D for day, W for week and M for month).
doi:10.1371/journal.pntd.0004100.g004
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specimens. The detections rates in urine and saliva then decreased and six weeks after the
beginning of the infection only 3% of the urine and saliva samples still tested positive. The
anti-DENV IgA antibody was detected in 30% and 10% of the plasma samples collected six
weeks and three months after the onset of fever, respectively.
All of the three kinetic curves of the anti-DENV IgG antibodies detection also had a similar
overall profile. The proportion of plasma samples that tested positive for IgG quickly increased
after the onset of the disease and between the three last collection points the values varied only
slightly from 82% at week 2 to 74% at month 3 after fever onset. The percentage of urine sam-
ples that tested positive for IgG during the first week was on average 11% lower compared to
the percentage of plasma samples that were IgG-positive. Globally both kinetic curves followed
the same trend. After a peak at 70.2% during the second week of the disease, the curve demon-
strated a regular decrease. In total, 25.9% of the samples tested positive one month after the
infection and only 10% after three months. The IgG detection rate in saliva increased continu-
ously from the 1st day of fever until the second week when it reached a plateau around 80%.
The sensitivity of the IgG test in saliva samples during the first two weeks of the disease was on
average 7% lower compared to the sensitivity of the assay in plasma specimens. From week 5,
the detection rate began to decrease and three months after the infection, 46% of the saliva
samples remained positive for anti-DENV IgG.
A total of 514 matched plasma, urine and saliva samples collected between DAOF 1 and
DAOF 103 were tested by AAC-ELISA. The results were positive in 39.9% (205/514, CI95 =
[35.6–44.3]), 23.3% (120/514, CI95 = [19.8–27.2]) and 24.1% (124/514, CI95 = [20.5–28.1]) of
the plasma, urine and saliva samples, respectively (Table 3). Concurrent testing of urine and
saliva specimens by AAC-ELISA increased sensitivity by 6.7% and 5.9% compared to testing
the urine or saliva samples alone and resulted in an overall decrease of the sensitivity to detect
anti-DENV IgA by 10%, compared to AAC-ELISA in plasma (decrease by 2.3% for samples
collected at day 2–3, by 7.5% at day 4–5, by 15.1% at day 6–7, by 7.3% during the 2nd week, by
25.8% six week after and by 5.5% three months after the onset of fever).
A total of 563 plasma, urine and saliva samples obtained from the same patients at the same
time-points, between DAOF 1 and DAOF 103, were tested by IgG indirect ELISA. Anti-DENV
IgG were detected in 56.8% (320/563, CI95 = [52.6–61.0]), 32.1% (181/563, CI95 = [28.3–
36.2]) and 42.8% (241/563, CI95 = [38.7–47.0]) of the plasma, urine and saliva samples, respec-
tively (Table 3). An overall detection rate of 49.7% (280/563, CI95 = [45.5–53.9]) was obtained
by combining the IgG results of paired urine and saliva specimens. The difference between the
sensitivity of the IgG test in plasma and in urine and saliva samples varied from a minimum of
9.1% (DAOF 2–3) and 3.4% (DAOF 2–3) to a maximum of 63.6% (month 3) and 30.6%
(month 3), respectively. The difference between the sensitivity of the assay in plasma and the
one obtained by combining results of paired urine and saliva was below 10% at all time-points
(minimal difference: 0% at DAOF 6–7; maximal difference: 7.5% at DAOF 4–5), except at
DAOF 0–1 and 3 months after the onset of fever when the difference reached 18.2% and
28.4%, respectively.
BRT analyses
The BRT analyses demonstrated that the three explanatory variables (“daof”, “status” and
“classif”) used in the study had a significant effect on the detection of DENV genome in plasma
by qRT-PCR. The variable “daof” (number of days after the onset of fever) had the higher rela-
tive importance (RI = 57.4%), followed by the immunological status (primary or secondary
infection) (RI = 25.8%) and then by the severity of the disease (RI = 16.8%) (Table 4). The par-
tial dependence plots suggested that there was a higher probability of detecting DENV-RNA in
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the plasma specimens obtained during the early febrile phase of the infection, in the samples
obtained from patients with a primary infection and in patients presenting with a severe form
of the disease (Fig 5). Models with four variables (“daof”, “status”, “classif” and “logvir” [viral
load in plasma]) were applied for the analysis of the qRT-PCR results in saliva and urine
Table 4. Results of the Boosted Regression Trees analysis for the detection of viral genome in plasma, urine and saliva.
Sample Mean Relative Importance (Standard deviation) Mean AUC* (Standard deviation)
daof status classif logvir
Plasma 57.36 (0.30) 25.80 (0.25) 16.84 (0.26) - 0.853 (0.007)
Urine 26.79 (0.22) 14.44 (0.19) 6.18 (0.15) 52.60 (0.31) 0.720 (0.008)
Saliva 18.49 (0.20) 14.05 (0.12) 3.22 (0.10) 64.24 (0.26) 0.820 (0.005)
daof: number of days between the onset of the fever and the time of sampling
status: immune status of the patient (primary versus secondary infection) determined by HIA
classif: disease classification according to the 1997 and the 2009 WHO guidelines
logvir: viral load measured by qRT-PCR (log10 cDNA copies/ml)
*Estimate of the model performance
doi:10.1371/journal.pntd.0004100.t004
Fig 5. Partial dependence plots for the most influential variables explaining viral genome detection in plasma, urine and saliva.
doi:10.1371/journal.pntd.0004100.g005
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samples. The variable “logvir” was the main explanatory variable (RI saliva = 64.2% and RI
urine = 52.6%) in both models, followed by “daof” (RI saliva = 18.5% and RI urine = 26.8%)
and “status” (RI saliva = 14.1% and RI urine = 14.4%) (Table 4). The model applied for saliva
specimens demonstrated a positive association between the RNA load measured in plasma and
the detection of the dengue genome in saliva. With the model used for urine specimens, a more
complex relationship with two maxima was observed: the first one for a viral load between 4
and 6 log10 cDNA copies/ml and the second one for a viral load greater than 8 log10 cDNA
copies/ml. The detection of the virus genome in saliva and urine samples was better during pri-
mary infections (Fig 5). The RI for the variable “classif” was only 3.2% and 6.2% in saliva and
urine specimens, respectively (Table 4). The partial dependence plots suggested a slightly better
detection of DENV-RNA in the urine of patients experiencing a severe form of the disease (Fig
5).
The best BRT model for NS1 detection in plasma was obtained by using the variables
“daof”, “classif” and by replacing the variable “status” by the continuous variable “IgG” (level
of IgG antibodies in the plasma specimens estimated by the ELISA OD value). The relative
importance of the variable “IgG” was 89.3% and the partial dependence plot demonstrated a
nearly linear decreasing association with the detection of NS1 protein (Table 5, Fig 6). The vari-
ables “daof” and “classif” had a RI of 8.0% and 2.7%, respectively. The severity of the disease
(variable “classif”) can be considered as having a negligible effect on the detection of the NS1
protein in the plasma samples. The BRT models used for NS1 antigen detection in saliva and
urine specimens were built with the variables “daof”, “status”, “classif” and “logNS1” (NS1 pro-
tein concentration in plasma). The higher RI in both models was obtained for the continuous
variable “logNS1” (RI = 67.3% and 64.6% for the saliva and urine models, respectively)
(Table 5). The partial dependence plots demonstrated a positive association between NS1 pro-
tein concentration in plasma samples and detection of NS1 antigen in saliva and urine speci-
mens (Fig 6). The second main explanatory variable identified was “daof” (RI = 20.9% and
25.4% for the saliva and the urine models, respectively) with an optimal detection of the NS1
protein being between the 3rd and the 8th day after the onset of fever, in both the saliva and the
urine samples (Table 5, Fig 6). The contribution to the models of the variables “status” and
“classif” was very low (Table 5).
In all of the BRT models generated for anti-DENV antibodies detection in the three differ-
ent body fluids, the impact of the explanatory variable “classif” (severe versus non-severe den-
gue) was negligible. The detection of IgG in plasma specimens was explained by the variables
Table 5. Results of the Boosted Regression Trees analysis for the detection of NS1 antigen in plasma, urine and saliva.
Sample Mean Relative Importance (Standard deviation) Mean AUC*(Standard deviation)
daof status classif IgG logNS1
Plasma 52.59 (0.19) 43.36 (0.30) 4.04 (0.23) - - 0.826 (0.004)
Plasma 8.02 (0.16) - 2.71 (0.08) 89.27 (0.20) - 0.895 (0.003)
Urine 25.38 (0.29) 7.67 (0.28) 2.32 (0.15) - 64.63 (0.34) 0.751 (0.006)
Saliva 20.94 (0.75) 9.93 (0.50) 1.83 (0.24) - 67.30 (0.13) 0.730 (0.004)
daof: number of day between onset of fever and sampling
status: immune status of the patient determined by HIA
classif: disease classification according to the 1997 and the 2009 WHO guidelines
IgG: anti-DENV IgG quantity in plasma estimated by optical density in indirect ELISA
logNS1: NS1 concentration in plasma (log10 ng/ml)
*Estimate of the model performance
doi:10.1371/journal.pntd.0004100.t005
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“daof” and “status” with a close relative importance (47.2% and 49.3%, respectively) (Table 6).
The partial dependence plots showed that the detection of IgG in plasma was associated with
secondary infection and that IgG antibodies were detected from one week until the end of the
follow-up period (Fig 7). For the detection of IgM in plasma specimens, the variable “daof”
appeared to be the only explanatory variable and was associated with a RI of 95.4%. The RIs of
the variables “status” and “classif” were negligible at 3.3% and 1.4% (Table 6). The detection of
anti-DENV IgA antibodies in plasma samples was mainly explained by the variable “daof”
(RI = 69.8%) and was the highest between one and four weeks after the onset of fever (Table 6,
Fig 7). The immune status of the patient (secondary infection) also contributed to explain the
ability to detect IgA antibodies (RI = 26.2%) (Table 6, Fig 7). The detection of antibodies in
saliva samples was linked mainly to the level of the corresponding class of immunoglobulin in
plasma (IgG detection: RI = 50.8%; IgM detection: RI = 68.5%; IgA detection: RI = 58.4%). Sim-
ilarly, the detection of IgA antibody in urine samples correlated with the titer of IgA in plasma
(RI = 60.2%). The relative importance of plasmatic IgG level appeared to be only 20.3% for the
detection of IgG in urine specimens. The main variables associated with the presence of IgG in
urine samples were the immunological status (RI = 42.1% in secondary infections) and the date
of sampling (RI = 36%) (Table 6, Fig 7).
Fig 6. Partial dependence plots for the most influential variables explaining NS1 antigen detection in plasma, urine and saliva.
doi:10.1371/journal.pntd.0004100.g006
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Two BRT models were used to identify factors influencing NS1 concentration (NS1 model,
variable “logns1”) and the RNA load (RNA model, variable “logvir”) in plasma samples during
the acute febrile phase of the disease (DAOF 0–5). Both models were built with the explanatory
variables “daof”, “classif” and “igg”. In both models the higher RI was obtained for the variable
“igg” (RI = 85.2% and 77.3% for the NS1 and the viral RNA models, respectively), followed by
the variable “daof” (RI = 8.5% and 20.9% for the NS1 and the viral RNA models, respectively)
and the variable “classif” (RI = 6.3% and 1.8% for the NS1 and viral RNA models, respectively)
(S8 Table). The partial dependence plot analysis demonstrated that higher NS1 concentrations
and RNA loads were associated with very low level of anti-DENV IgG (OD<0.15) (S3 Fig).
Discussion
One of the objectives of this study was to assess the possibility to use saliva or urine specimens
instead of blood for the diagnosis of dengue infections in specific situations. The evaluation
included the assays most routinely used for dengue diagnosis: viral genome detection by
qRT-PCR, virus isolation in mosquito cell lines, NS1 antigen and anti-DENV antibody detec-
tion by ELISA methods. In order to generate the strongest data possible, a large number of
samples obtained from children hospitalized in Cambodia for dengue of varying degrees of
severity were tested. This is the first study in which plasma, urine and saliva obtained from the
same patients, at the same time-points, were tested in parallel and the results compared to esti-
mate the performances of the various dengue diagnostic assays.
Saliva and urine specimens are obtained through non-invasive procedures that require the
patient’s participation. If devices for urine sampling in infants exist and if saliva can be col-
lected with small specific swabs, one may consider that in the youngest children the collection
of capillary blood on filter paper after a finger-prick could be a better alternative to venipunc-
ture than urine or saliva sampling.
This is the first study that aimed to detect the DENV genome in such a large number of
saliva samples and to comprehensively describe the kinetics of DENV genome detection in this
body fluid. Previously, Anders et al. attempted to detect the DENV genome in saliva swab spec-
imens obtained from six patients with confirmed DENV infection but all samples tested
Table 6. Results of the Boosted Regression Trees analysis for the detection of anti-DENV antibodies in plasma, urine and saliva.
Antibody Sample Mean Relative Importance (Standard deviation) Mean AUC*(Standard deviation)
daof status classif antibodies
IgG Plasma 47.26 (0.10) 49.31 (0.12) 3.43 (0.06) - 0.910 (0.002)
Urine 36.00 (0.12) 42.05 (0.18) 1.66 (0.03) 20.29 (0.16) 0.895 (0.001)
Saliva 23.49 (0.14) 24.42 (0.14) 1.33 (0.04) 50.76 (0.23) 0.908 (0.002)
IgM Plasma 95.37 (0.28) 3.26 (0.27) 1.37 (0.11) - 0.883 (0.003)
Saliva 26.49 (0.13) 4.62 (0.08) 0.39 (0.03) 68.51 (0.17) 0.878 (0.002)
IgA Plasma 69.76 (0.20) 26.24 (0.09) 4.00 (0.17) - 0.907 (0.002)
Urine 23.68 (0.03) 15.59 (0.10) 0.55 (0.07) 60.18 (0.10) 0.904 (0.002)
Saliva 26.94 (0.11) 11.54 (0.06) 3.08 (0.05) 58.44 (0.135) 0.899 (0.002)
daof: number of days between the onset of the fever and the day of sampling
status: immune status of the patient determined by HIA (primary versus secondary infection)
classif: severity of the disease according to the 1997 and the 2009 WHO guidelines
antibodies: level of the corresponding immunoglobulin isotype in the plasma estimated by the measure by ELISA of the optical density
*Estimate of the model performance
doi:10.1371/journal.pntd.0004100.t006
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Fig 7. Partial dependence plots for the most influential variables explaining anti-DENV antibodies detection in plasma, urine and saliva.
doi:10.1371/journal.pntd.0004100.g007
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negative [26]. The DENV genome was successfully detected from saliva samples in only few
instances and described in some cases reports [20,23] as well as in one very recent study per-
formed on only 14 patients [19]. We demonstrated here that, as in the plasma, the sensitivity of
the genome detection in saliva specimens was the highest during the early acute phase of the
infection (i.e., 63.9% at day 3 post-fever; approximately 60% during the four first days of the
disease) and then decreased over time before the RNA became undetectable 10 days after the
onset of fever. The curves of the sensitivity of the RNA detection in plasma and saliva speci-
mens had very similar profiles over time. Nevertheless, the sensitivity of the qRT-PCR in saliva
was on average 40% lower than in plasma when the specimens were tested between DAOF0
and DAOF8. The BRT analysis indicated that the higher the RNA load in plasma, the higher
the probability of detecting the viral RNA in saliva samples was.
Some authors showed in a limited number of patients and samples that the DENV genome
could be detected in urine specimens [19,20,22–24]. Hirayama et al. described the results
obtained with 77 urine samples collected from 53 patients and described DENV genome excre-
tion kinetics similar to the one we report here, i.e. a delayed excretion of the viral genome in
urine by comparison to blood [22]. In some cases, the DENV genome was still detectable in
urine samples while the serum already turned negative by qRT-PCR [20,22,24]. In our study,
we observed this pattern in three patients whose plasma collected at the time of hospital dis-
charge (up to10 days after onset of fever) tested negative, whereas their urine collected at the
same time was positive. The sensitivity of the confirmation of the dengue infection by viral
genome detection improved from 79.6% to 82.6% when qRT-PCR was performed in both
urine and plasma samples collected after the 5th day of fever, compared to qRT-PCR in plasma
alone. Nevertheless, even after DAOF 5, plasma remained the best biological fluid to use for
dengue diagnosis. Indeed, out of the 116 pairs of urine and plasma samples collected during
the early convalescent phase of the disease from the same patients, 63.8% were concordant (i.e.,
both urine and plasma samples tested positive or both urine and plasma samples tested nega-
tive). Only three pairs demonstrated discordant results with an advantage for urine over
plasma whereas 39 pairs gave discordant results in favor of plasma (i.e. the urine sample tested
negative whereas the corresponding plasma sample tested positive). After discharge from the
hospital, the urine sample of three other patients still tested positive (two patients at DAOF 13
and one patient at DAOF 16) but the comparison with plasma was not possible as blood sam-
ples were unavailable for these time points. All patients whose saliva samples tested positive
also had detectable levels of RNA in the plasma samples collected at the same time-points.
Thus, testing saliva in addition to the plasma samples did not significantly improve diagnostic
sensitivity. When it is not possible to get blood samples, testing concurrently both urine and
saliva specimens by qRT-PCR could offer an interesting alternative as the overall diagnostic
sensitivity was 76.1% during the acute phase of the disease (DAOF 0–5) and 59.4% during the
early convalescent phase (DAOF 6–12). Alternatively, the analysis of sequential urine or saliva
specimens could also provide, in specific situations, some acceptable results as 57% of the
patients had at least one positive urine sample and almost 69% of them had a least one saliva
sample that tested positive in the course of the disease.
To date, DENV has never been isolated from urine or saliva. Two unsuccessful attempts to
isolate the DENV from urine and one attempt to isolate the virus from saliva were previously
reported by Hirayama et al. and Korhonen et al. [19,22]. The low RNA loads in urine and saliva
observed in our study could provide one explanation to the inability to isolate the virus after
inoculation of the samples onto C6/36 or Vero E6 cells [39]. Nevertheless, the absence of infec-
tious DENV particles from urine and saliva specimens will be attested only after unsuccessful
inoculation of the RNA-positive samples into mosquitoes, as this method is recognized as the
most sensitive for DENV isolation [40]. Direct toxicity on C6/36 or Vero E6 cells of some urine
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and saliva components could also explain the inability to isolate the virus from those samples.
In our study, urine samples were dialyzed before inoculation in order to eliminate potentially
toxic components and saliva samples were inoculated after dilution with culture media to
avoid excessive direct toxicity. Furthermore, the controls included in the series of culture plates
provided evidence that a premature cell death was not responsible for the absence of virus
detection. It rather appeared that a low viral load was at the origin of an absence of detection of
infectious virus in saliva and urine specimens. But it is also possible that the DENV RNA
detected by qRT-PCR in urine was “free” viral RNA that was able to go through the glomeruli
while virus particles, especially those embedded in large immune complexes, were stopped.
The detection of NS1 protein in saliva and/or urine samples has already been reported in
three studies bearing on a limited number of patients [19,21,26] and recently in a larger study
including urine samples from 96 patients [41]. Here, we demonstrate that the sensitivity of
NS1 detection in saliva and urine samples follow a similar trend over time. Diagnostic sensitiv-
ity increased progressively until DAOF 4 to reach a maximum of 25% in urine and 40% in
saliva samples, and then decreased until NS1 became undetectable, ten days after fever onset.
The sensitivity NS1 antigen detection in urine and saliva samples observed in our study was
lower than the one reported previously. Anders et al. reported 64.7% (55/85) of saliva samples
positive for NS1 protein when testing patients with a positive NS1 antigenemia [26]. In our
study, only 25.8% (99/383) of the paired plasma and saliva samples tested both positive, at the
same time-point. Chuansumrit et al., Korhonen et al. and Saito et al. previously evaluated the
sensitivity of NS1 detection in urine using the same commercial ELISA kit. Chuansumrit et al.
and Korhonen et al reported sensitivities of 65.6% and 54.2%, respectively [19,21]. Saito et al.
described a positive detection rate of NS1 ranging from 13% to 43% according to days after dis-
ease onset. The highest detection rate was obtained on days 6–10 after disease onset [41]. As
observed for the RNA load, NS1 protein concentrations measured in urine and saliva samples
were much lower than those measured in plasma specimens. The multivariate analysis using
BRT identified the NS1 concentration in plasma as the main factor explaining the possibility of
detecting the viral protein in urine and saliva. Korhonen et al. also showed that the NS1 con-
centration in urine positively correlated with the concentration in urine of the total proteins
[19]. In their study, Chuansumrit et al reported a higher NS1 detection rate in urine samples
obtained from patients with DHF than in patients presenting with a mild DF [21]. Our statisti-
cal analysis performed in a large patient series did not evidence a higher probability of detect-
ing NS1 in the urine of patients experiencing a severe form of the disease (DHF and DSS) than
in those presenting with a mild infection. We decided not to concentrate urine specimens
before testing for NS1 in order to keep the ELISA protocol as easy and cheap as possible to
meet the “real-life” conditions of most endemic countries which are also often developing
countries. Saito et al. investigated the benefit of urine concentration prior to NS1 capture by
ELISA with 37 paired concentrated and non-concentrated urine samples. Concentration
allowed the detection of NS1 antigen in three samples that tested negative before concentration
[41]. For well-equipped laboratories that may be willing to use urine as a replacement to blood
for DENV infection confirmation, it would be important to further develop of a fast and simple
method for NS1 protein concentration.
Our study also shows that 2/3 of the plasma samples that tested positive by qRT-PCR also
tested positive for NS1 detection; that half of the saliva samples that tested positive by
qRT-PCR also tested positive by NS1 capture ELISA, but that NS1 was detected in less than
30% of the urine samples that tested positive by qRT-PCR. The discrepancy between the RNA
and NS1 detection in urine samples obtained from patients with detectable viremia suggests
that these two biological markers of dengue infection are potentially released in urine through
different mechanisms that remain to be clarified.
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Similarly to Vasquez et al., we were unable to detect anti-DENV IgM in urine specimens
[25]. The sensitivity of the IgM and the IgG assays in saliva was close to those obtained in
plasma samples. The sensitivity of the IgA serology in both urine and saliva was 65% at the
peak point when it was almost 90% in plasma. This is in agreement with the data previously
described by Vasquez et al. as well as by Balmaseda et al. [25,27,42]. Multivariate analysis dem-
onstrated that the probability of detecting antibodies in saliva specimens depended essentially
on antibodies titers in the plasma. Cuzzubbo et al. reported previously that salivary IgG levels
correlated well with serum HI titer [43]. This study also showed that IgG detection in saliva
could be used to distinguish between primary and secondary DENV infection. Our BRT analy-
sis confirms this result. Balmaseda et al. investigated the use of IgG and IgM detection in saliva
to evaluate DENV infection incidence during a serological survey and demonstrated that anti-
DENV IgG detection in saliva was a good tool to measure the incidence of dengue in a commu-
nity cohort [27]. The anti-DENV IgG antibody urinary excretion curve follows the same trend
than that of IgG in plasma during the first week of the disease. Subsequently, urinary excretion
of IgG decreases over time while it remains stable in plasma. Three months after disease onset,
76.1% of the patients had detectable anti-DENV IgG in their plasma whereas only 12.5% of
them still tested positive in their urine. The present study is the first to document the kinetics
of anti-DENV antibodies until the third month after fever onset. Multivariate analysis showed
that the detection of anti-DENV IgG in urine was not primarily associated with antibody titers
in plasma but with the immune status of the patient and with the time of sampling after the
onset of the disease. Antibodies are high-molecular-weight (HMW) proteins. In physiologic
conditions, these proteins are almost completely restricted from filtration by the glomerular
barrier and only a very small quantity of it can normally be detected in urine. The presence of
macromolecules such as IgG and IgA in urine could reflect an alteration of the glomerular bar-
rier, with or without tubular cells impairment. IgM is a pentameric immunoglobulin of very
high molecular weight (950 kDa) and its detection in urine would reflect a severe glomerular
injury [44]. This probably explains why IgM were not detected in the patients included in this
study as none of them had any record of severe renal impairment during the course of their
illness.
In this study, as in most of those reported previously, saliva specimens were collected by
direct spitting. Only Anders et al. collected saliva using swabs and reported results significantly
different from ours [26]. These authors were unable to detect DENV genome by RT-PCR but
obtained a higher sensitivity for NS1 (i.e., 64.7%). Michishige et al. demonstrated that saliva
samples collected by different methods of sampling were not equivalent in terms of total pro-
teins and secretory IgA concentrations [45]. These different methods of saliva sampling should
be compared in order to better define which one is the most suitable to perform each test.
The early identification of an ongoing DENV infection and a rapid implementation of spe-
cific clinical management procedures are key to ensure the best clinical outcome [1]. The cur-
rent lack of simple and reliable prognostic marker to predict the risk of evolution of the patient
towards a severe form of the disease makes the clinical management of the DENV infections
extremely challenging, especially during epidemics and in countries with weak health systems.
Among all the parameters evaluated within this study, the NS1 protein would theoretically be
the ideal candidate for early diagnosis as this antigen is a marker of acute dengue infection that
is easy and fast to detect. Anti-DENV antibodies usually appear only after the patient has
already progressed toward the critical phase of infection. Conflicting results have been reported
on a possible association between the concentration of free NS1 circulating in plasma and the
disease severity. Although several studies reported a positive association [46,47], other studies
have not [48–50]. In our study, which included a large number of patients experiencing pri-
mary and secondary infections, the multivariate analysis using BRT suggested that disease
Use of Urine and Saliva for Dengue Diagnosis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004100 September 25, 2015 24 / 30
severity does not influence NS1 concentration in plasma during the acute phase of the disease
but that plasmatic titers of anti-DENV IgG was the most important factor to explain free NS1
protein concentration in blood. Indeed, undetectable or very low levels of anti-DENV IgG anti-
bodies were associated with higher concentrations of free NS1, the only fraction that is detected
by the assays, while the NS1 fraction that is trapped into the immune-complexes is not cap-
tured in the diagnostic tests.
A potential association between the DENV-RNA load measured during the acute phase of
the disease and disease severity has also been suggested, but the scientific literature reports con-
flicting findings [46,48,51,52]. Our BRT analysis suggests that the severity of infection was not
associated to the RNA load in plasma during the acute phase of the disease (DAOF 0–5). The
level of anti-DENV IgG was the main parameter explaining the RNA load in the plasma speci-
mens during the acute phase of the disease, with an inverse relationship like the one observed
for NS1. The present report is the first to investigate the relationship between the NS1 concen-
tration and the RNA load in plasma and the severity of the disease by using a multivariate anal-
ysis that included the anti-DENV IgG level. These findings require to be confirmed during
other epidemics involving more patients and other infecting serotypes as this factor may affect
both the RNA load and the NS1 concentration [53,51].
Our study shows that urine and saliva could be considered for the diagnosis of dengue infec-
tion in some situations when optimal sensitivity is not necessarily required. These two body
fluids provide different type of information. The saliva essentially mirrors what happens in the
blood, which is not surprising as approximately 2.5% of the whole saliva is composed of gingi-
val fluid, a protein-rich serum transudate, therefore reflecting the protein pattern in the serum.
Antibodies titers in saliva are thus a few orders of magnitude lower compared to those in
serum [54]. It was estimated that the IgA, IgG and IgM levels in saliva specimens were approxi-
mately 1/10, 1/800 and 1/400 of those measured in serum [55]. In urine, the detection of mac-
romolecules such as IgGs (150 kDa), IgAs (320 kDA) and NS1 protein (300 kDa) most likely
reflects an alteration of the glomerular filtration barrier which has three major components:
the glomerular endothelial cells (GECs), the glomerular basement membrane and the podo-
cytes. One of the characteristics of GECs is the presence of numerous fenestrations, which in
theory should allow the passage of large molecules. GECs, however, are coated by a glycocalyx
layer composed of glycosaminoglycans, which in normal conditions impedes the leakage of
macromolecules. Abnormal disruption of the glycocalyx restores the passage of big molecules
through the fenestration of the GECs [56]. High-molecular-weight proteins cannot pass
through the podocytes barrier in normal conditions, but the accumulation of such macromole-
cules probably induces an alteration of this structure, which in turn leads to a proteinuria [57].
It has been suggested that during dengue infection, impairment of the glycocalyx layer on
endothelial cells could occur. Both the virus itself and the NS1 antigen are known to fix
heparan sulfate, a major glycosaminoglycan of the glycocalyx [58,59]. Moreover Wills et al.
observed an increased urinary heparan sulfate excretion in children with severe dengue infec-
tion compared to healthy control subjects, suggesting that an alteration of the glycocalyx layer
may occur in severe dengue infections [60]. The presence of circulating immune complexes
formed to eliminate the virus and the NS1 antigen may provide another possible explanation
to the alteration of the glomerular barrier. Cases of glomerulonephritis with glomerular
immune complex-type deposits have been reported during DENV infections [61]. Jessie et al.
also described the presence of viral antigen suggestive of the presence of immune complexes in
the kidney tubular cells from dengue-infected patients [62]. Further investigations are needed
on the potential interactions of dengue virus, immune complexes, and other components of
the immune response with heparan sulfate and other glycosaminoglycan of the glycocalyx but
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also with the other kidney cells to determine if subclinical kidney lesions do not occur more
often during DENV infection.
In this study we were not able to evaluate the performances of the different diagnostic meth-
ods for all four dengue virus serotypes as it was conducted using well-characterized and
sequential clinical samples prospectively collected during a DENV-1 epidemic, when the
DENV-2 and DENV-4 were circulating at lower level and no DENV-3 was detected.
The results of our study demonstrate that the diagnosis of dengue infection in urine and
saliva specimens is possible but we believe that there is certainly still a room for improvement
of these assays. Existing commercial rapid diagnostic tests (RDTs) designed to be used with
blood samples would probably require significant adjustments, as urine and saliva specimens
are very different from whole blood, plasma or serum. One of the main differences resides in
the huge difference in protein concentration. A Singaporean group has recently developed a
rapid test for the detection of anti-DENV IgG in saliva. The device gave good results in saliva
samples spiked with IgG but requires further optimization to detect IgG from the clinical sam-
ples of dengue-infected patients [63]. Recently, saliva samples were tested using a commercial
ELISA initially developed for IgG detection in blood and demonstrated 100% sensitivity and
specificity [64].
In conclusion, although the performances of the different diagnostic methods evaluated
here were not as good in saliva and urine as in plasma, results obtained with qRT-PCR and
with antibody detection could justify the use of these two body fluids for the diagnosis of den-
gue infection for instances such as outbreak investigations or in young children (once they are
old enough to comply to instructions), in addition to the situations when blood cannot be eas-
ily collected (e.g., lack of phlebotomist, refusal of the procedure, etc.). The disadvantage result-
ing from a slight decrease in the diagnostic confirmation performances when using molecular
and serological tests in urine and saliva samples instead of blood is partially balanced by the
ease to obtain these specimens and by the better compliance of the patient or by the number of
individuals that can be investigated during studies when non-invasive sample collection meth-
ods are used. Moreover, the modest sensitivity of the test can be offset by high prevalence dur-
ing the peak of an outbreak and/or when guided by competent clinicians. It results in high
predictive positive value, making this test a useful addition for biological diagnosis in field
conditions.
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